Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19104


This study will determine the effectiveness of the herb black cohosh for treating menopause-related anxiety symptoms in women. Study hypotheses: 1) Black cohosh will have a superior anti-anxiety effect compared to placebo. 2) Black cohosh will have a comparable safety profile to that of placebo.

Study summary:

During menopause, up to 90% of women will experience symptoms of anxiety, such as nervousness, irritability, fatigue, muscle aches, depression, and low libido. Concern over the safety and effectiveness of hormone replacement therapy for relieving these symptoms has caused many women to seek alternative medical treatments. Data suggest that black cohosh has a direct effect on the neurotransmitters and receptors involved in anxiety. This study will determine whether black cohosh can effectively treat anxiety symptoms in menopausal women. This study will last 12 weeks. Participants will be randomly assigned to receive either black cohosh or placebo daily for the duration of the study. Self-report scales will be used to assess participants' anxiety symptoms and quality of life at the beginning and end of the study.


Inclusion Criteria: - Currently experiencing menopause or postmenopausal - Have symptoms of menopause-related anxiety Exclusion Criteria: - Any form of generalized anxiety disorder (GAD) unrelated to menopause - Onset of GAD at least 3 years prior to menopause or at least 5 years after menstruation has stopped - Alcohol or drug dependence within 3 months prior to study entry - Allergy to black cohosh - History of hormone replacement therapy - Current use of vaginal estrogen cream or phytoestrogens - Current use of tranquilizers, antidepressants, or antianxiety therapies - Abnormal uterine bleeding - History of estrogen-dependent cancer - History of endometrial hyperplasia (abnormal increase in cells) or endometrial cancer - Rapidly growing uterine fibroids - Abnormal finding upon gynecological examination that would interfere with the study - Abnormal breast examination or mammogram - Any unstable medical condition



Primary Contact:

Principal Investigator
Jay D. Amsterdam, MD
University of Pennsylvania

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19104
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.